TCR2 Therapeutics (TCRR) Adds Dr. Axel Hoos to Board

Go back to TCR2 Therapeutics (TCRR) Adds Dr. Axel Hoos to Board

TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors

April 15, 2020 6:45 AM EDT

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Axel Hoos, M.D., Ph.D., to its Board of Directors. An immuno-oncology pioneer with broad business and scientific expertise, Dr. Hoos is recognized for launching the field through development of the anti-CTLA-4 ipilimumab, the first FDA-approved checkpoint immunotherapy.

"With TCR2 at a significant inflection point in the growth of its clinical... More